Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

558

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: Daclatasvir
DRUG: Daclatasvir
DRUG: Placebo
DRUG: peg-interferon alfa-2a
DRUG: ribavirin

Sponsor

Bristol-Myers Squibb